🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Celina Ang

Icahn School of Medicine at Mount Sinai

ORCID: 0000-0001-6057-6026

MedicineBiochemistry, Genetics and Molecular BiologyChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling”.

Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1351

N/A

0DataRank · unranked

65 citations

Tamer A. Ahmed, Maxwell R. Tucker, Peter M.U. Ung, Min Xiao, Zoi Karoulia +12 more

A Drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma

iScience(2021)10.1016/j.isci.2021.102212

N/A

0DataRank · unranked

38 citations

Peter Smibert, Andrew Uzilov, Alexander Teague, Sindhura Gopinath, Yevgeniy Antipin +25 more

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Hepatology Communications(2023)10.1097/hc9.0000000000000302

N/A

0DataRank · unranked

11 citations

Bernhard Scheiner, Antonio D ́Alessio, Claudia Angela Maria Fulgenzi, Martin Schönlein, Lorenz Kocheise +31 more

Data from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

(2023)10.1158/2159-8290.c.6549364

N/A

0DataRank · unranked

1 citations

Tamer A. Ahmed, Maxwell R. Tucker, Peter M.U. Ung, Min Xiao, Zoi Karoulia +12 more